These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 10623699

  • 1. Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center.
    Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J.
    J Clin Oncol; 2000 Jan; 18(1):102-5. PubMed ID: 10623699
    [Abstract] [Full Text] [Related]

  • 2. An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions.
    Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J.
    J Cancer Res Clin Oncol; 1999 Jul; 125(7):427-9. PubMed ID: 10394964
    [Abstract] [Full Text] [Related]

  • 3. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
    Bookman MA, Kloth DD, Kover PE, Smolinski S, Ozols RF.
    Ann Oncol; 1997 Jun; 8(6):611-4. PubMed ID: 9261533
    [Abstract] [Full Text] [Related]

  • 4. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments.
    Feldweg AM, Lee CW, Matulonis UA, Castells M.
    Gynecol Oncol; 2005 Mar; 96(3):824-9. PubMed ID: 15721432
    [Abstract] [Full Text] [Related]

  • 5. Premedication strategy for weekly paclitaxel.
    Quock J, Dea G, Tanaka M, Gandara D, Lara P, Lau D.
    Cancer Invest; 2002 Mar; 20(5-6):666-72. PubMed ID: 12197222
    [Abstract] [Full Text] [Related]

  • 6. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies.
    Robinson JB, Singh D, Bodurka-Bevers DC, Wharton JT, Gershenson DM, Wolf JK.
    Gynecol Oncol; 2001 Sep; 82(3):550-8. PubMed ID: 11520154
    [Abstract] [Full Text] [Related]

  • 7. [Paclitaxel hypersensitivity reactions in patients with advanced ovarian carcinoma].
    Kobierski J, Majdak E, Mielcarek P, Emerich J.
    Ginekol Pol; 2002 Nov; 73(11):1015-20. PubMed ID: 12722392
    [Abstract] [Full Text] [Related]

  • 8. Randomized, Controlled Trial of Dexamethasone Versus Dexamethasone Plus Hydrocortisone as Prophylaxis for Hypersensitivity Reactions Due to Paclitaxel Treatment for Gynecologic Cancer.
    Jeerakornpassawat D, Suprasert P.
    Int J Gynecol Cancer; 2017 Oct; 27(8):1794-1801. PubMed ID: 28704328
    [Abstract] [Full Text] [Related]

  • 9. Hypersensitivity reaction to paclitaxel: nursing interventions.
    Myers JS.
    Clin J Oncol Nurs; 2000 Oct; 4(4):161-3. PubMed ID: 11261096
    [Abstract] [Full Text] [Related]

  • 10. Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.
    Berger MJ, Vargo C, Vincent M, Shaver K, Phillips G, Layman R, Macrae E, Mrozek E, Ramaswamy B, Wesolowski R, Shapiro CL, Lustberg MB.
    Support Care Cancer; 2015 Jul; 23(7):2019-24. PubMed ID: 25519756
    [Abstract] [Full Text] [Related]

  • 11. Successful re-treatment with taxol after major hypersensitivity reactions.
    Peereboom DM, Donehower RC, Eisenhauer EA, McGuire WP, Onetto N, Hubbard JL, Piccart M, Gianni L, Rowinsky EK.
    J Clin Oncol; 1993 May; 11(5):885-90. PubMed ID: 8098057
    [Abstract] [Full Text] [Related]

  • 12. A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel.
    Kwon JS, Elit L, Finn M, Hirte H, Mazurka J, Moens F, Trim K.
    Gynecol Oncol; 2002 Mar; 84(3):420-5. PubMed ID: 11855881
    [Abstract] [Full Text] [Related]

  • 13. Successful desensitization to docetaxel after severe hypersensitivity reactions in two patients.
    Reeves DJ, Callahan MJ, Sutton GP.
    Am J Health Syst Pharm; 2012 Mar 15; 69(6):499-503. PubMed ID: 22382481
    [Abstract] [Full Text] [Related]

  • 14. Single-dose dexamethasone paclitaxel premedication.
    Micha JP, Rettenmaier MA, Dillman R, Fraser P, Birk C, Brown JV.
    Gynecol Oncol; 1998 May 15; 69(2):122-4. PubMed ID: 9600818
    [Abstract] [Full Text] [Related]

  • 15. Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experience.
    Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J.
    Semin Oncol; 1997 Oct 15; 24(5 Suppl 15):S15-26-S15-29. PubMed ID: 9346218
    [Abstract] [Full Text] [Related]

  • 16. Preliminary experience with a modified premedication protocol that included intravenous diphenhydramine and calcium bromide for the prophylaxis of paclitaxel-related hypersensitivity reactions.
    Sasada S, Hirashima T, Nakamura Y, Takimoto T, Furukawa M, Kobayashi M, Nitta T, Matsui K, Kawase I.
    Int J Clin Oncol; 2007 Aug 15; 12(4):274-8. PubMed ID: 17701006
    [Abstract] [Full Text] [Related]

  • 17. Dose reduction of steroid premedication for paclitaxel: no increase of hypersensitivity reactions.
    Köppler H, Heymanns J, Weide R.
    Onkologie; 2001 Jun 15; 24(3):283-5. PubMed ID: 11455223
    [Abstract] [Full Text] [Related]

  • 18. Cetirizine versus diphenhydramine in the prevention of chemotherapy-related hypersensitivity reactions.
    Durham CG, Thotakura D, Sager L, Foster J, Herrington JD.
    J Oncol Pharm Pract; 2019 Sep 15; 25(6):1396-1401. PubMed ID: 30419768
    [Abstract] [Full Text] [Related]

  • 19. Paclitaxel premedication regimens.
    Boehm DK, Maksymiuk AW.
    J Natl Cancer Inst; 1996 Apr 03; 88(7):463-5. PubMed ID: 8618242
    [No Abstract] [Full Text] [Related]

  • 20. Is a low dose of dexamethasone sufficient to prevent paclitaxel-related hypersensitivity reactions? A retrospective study in patients with gynecologic malignancy.
    Xiao D, Yang Z, Shi Y, Yang W, Zhang Y.
    Expert Rev Clin Pharmacol; 2024 Apr 03; 17(5-6):525-532. PubMed ID: 38652518
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.